Skip to main content
Melanie Kier, MD, Oncology, New York, NY, The Mount Sinai Hospital

MelanieWainKierMDMBA

Oncology New York, NY

Breast Cancer, Gynecologic Cancer, Hematologic Oncology

Hematology-Oncology Fellow

Dr. Kier is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kier's full profile

Already have an account?

  • Office

    Mount Sinai Medical Center - Division of Hematology and Medical Oncology
    One Gustave L. Levy Place, Box 1128
    New York, NY 10029
  • Is this information wrong?

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2020 - 2023
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2017 - 2020
  • Wharton School of the University of Pennsylvania
    Wharton School of the University of PennsylvaniaMBA, Healthcare Management, Forte Fellowship, 2015 - 2017
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2017
  • Yale University
    Yale UniversityBA, Economics, Cum Laude, 2006 - 2010

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2020 - 2026
  • PA State Medical License
    PA State Medical License 2017 - 2020
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Forte Fellow Forte Foundation, 2015-2017

Publications & Presentations

PubMed

Journal Articles

  • A. Case of Paraneoplastic Cerebellar Disorder in Ovarian Carcinoma with a Negative Serum Paraneoplastic Antibody Panel and a Positive CSF Anti-Yo Antibody Titer  
    Berger N*, Kier MW*, Kim L, Tiersten A., Journal of Gynecological Oncology, 7/18/2022

Abstracts/Posters

  • Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer
    Kier MW, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman BS, Yang Y, Fink MY, Zhou X, Newman S, Chen R, Schadt E, Oh WK, Tiersten A, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 6/6/2022
  • Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score (RS) in early breast cancer (EBC)
    Patel R, Hovstadius M, Kier MW, Moshier E, Zimmerman BS, Cascetta KP, Jaffer S, Sparano JA, Tiersten A, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 6/6/2022
  • The Promising Use of Hospital at Home in an Oncology Setting
    Kier MW, Lubetsky S, Schiller G, Siu AL, Ornstein KA, Smith CB, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 6/4/2022
  • Join now to see all

Other

  • Training Future Quality Leaders in Oncology Starts with Fellowship 
    Kessler AJ*, Kier MW*, Smith CB, Bhardwaj AS, Expert Editorial in ASCO Daily News
    https://dailynews.ascopubs.org/do/10.1200/ADN.21.200725/full/
    10/7/2021
  • Utilization of Pathologist to Help Grieving Family Understand Autopsy Finding 
    Kier MW, Wain S, Oral Presentation
    Planetree International Conference, October 2016

Hospital Affiliations